Terns Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Terns Pharmaceuticals has a total shareholder equity of $218.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $230.9M and $12.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$225.30m |
| Equity | US$218.68m |
| Total liabilities | US$12.20m |
| Total assets | US$230.88m |
Recent financial health updates
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Aug 18
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
May 03Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Recent updates
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Aug 18Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
May 03Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03Terns Pharmaceuticals: The Easy Money Has Been Made
Sep 20Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08
Aug 08Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study
Jun 14Financial Position Analysis
Short Term Liabilities: TERN's short term assets ($230.2M) exceed its short term liabilities ($11.0M).
Long Term Liabilities: TERN's short term assets ($230.2M) exceed its long term liabilities ($1.2M).
Debt to Equity History and Analysis
Debt Level: TERN is debt free.
Reducing Debt: TERN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TERN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TERN has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 16.3% each year.